The consortium enjoyed a constructive meeting at the end of November, hosted by Prof Beppe Remuzzi and his team at the Insitute Mario Negri in Bergamo. Progress was reviewed, plans were refined and preparations for the next six months of collaboration were made.
The photo shows the consortium at the Institute Mario Negri.
NEPHSTROM partner NHSBT received good coverage in the UK and international diabetes media in October.
Diabetes breakthrough: New stem cells that can halt kidney disease about to be tested
express.co.uk, 19 Oct 2015, UK, Keyword: NHS Blood and Transplant, Journalist: Jon Austin
Dr Eric Austin, head of Stem Cell Immunotherapy at the Advanced Therapy Unit within the Stem Cells and Immunotherapies department at NHS Blood and Transplant’s site in Speke, Liverpool, said: “This is an exciting project for us to be involved with – especially as the treatment has the potential to lead to life saving outcomes for a major illness.”
STEM CELLS TRIAL TO HELP DIABETES PATIENTS WITH KIDNEY DISEASE
PA News Wire, 20 Oct 2015
The project also enjoyed coverage in
- The Diabetes Times
- Diabetes Forum.com
- StarMine News
- PharmaTimes Digital
This month (November) sees the consortium assemble in Bergamo for our second plenary meeting (the first one since the kick-off in Dublin). The meeting is hosted by Beppe Remuzzi and his team at the Istituto Mario Negri (IRFMN). We look forward to catching up on all the news from the cell production centres, and to putting in place the facilities to carry out the clinical trial (led, of course, by IRFMN).
The project received excellent coverage from the BBC on 20 October, focusing on the cell production taking place at NHSBT.
The item (at http://www.bbc.com/news/health-34570550) gives a concise overview of the project, and quotes both coordinator Prof Tim O’Brien (NUIG) and the NHSBT’s Dr Eric Austen.
LMUM distributed a press release about NEPHSTROM, aimed at the German-language press and public.
The full text was as follows:
Neue Klinische Studie zur Stammzelltherapie bei diabetischer Nierenschädigung
24.06.2015 – Die Arbeitsgruppe um Prof. Hans-Joachim Anders am Nephrologischen Zentrum der Medizinischen Klinik und Poliklinik IV leitet ein Teilprojekt in dem EU-Projekt NEPHSTROM (Novel Stromal Cell Therapy for Diabetic Kidney Disease).
Präklinische Arbeiten und eine erste klinische Studie zur Stammzelltherapie bei diabetischer Nierenschädigung werden durch das Horizon-2020-Programm der Europäischen Union mit 6 Millionen Euro gefördert. Das auf vier Jahre ausgelegte Projekt wird die durch Forscher an der National University of Ireland in Galway (NUI Galway) entwickelte Stammzelltherapie auf ihre klinische Sicherheit und Wirksamkeit überprüfen.
Eine diabetische Nephropathie (DN) entwickeln 25 bis 40 Prozent aller Patienten mit Diabetes weltweit, häufig mit der Folge eines Nierenversagens und damit einer wesentlichen Todesursache bei Diabetes. “Wir hoffen, mit einer einmaligen intravenösen Injektion von Mesenchymalen Stammzellen den Verlauf der diabetischen Nierenschädigung günstig beeinflussen zu können”, sagt Prof. Anders, Oberarzt des Nephrologischen Zentrums am LMU-Klinikum.
The launch of the NEPHSTROM project received further excellent coverage in the media, social media and EU vehicles. Coverage now includes all the following:
RTÉ Radio 1 News (RTE is the Irish national broadcaster)
8 June, at 7am and 8am 9am (during Morning Ireland) clips are 1 minute 30 seconds long
RTÉ One News, 8 June
The Irish Times, 8 June
The Irish Examiner, 8 June
UTV Ireland online, 8 June
The Journal.ie, 8 June
The Irish Mirror
www.newstalk.com (Newstalk Radio, an Irish nationwide radio station)
EU news you can use – the newsletter of the EU Commission Representation in Ireland
Our sister project REDDSTAR and Leiden University Medical Center are co-organizing EU MSC2 2015, a meeting in Leiden, NL on September 7th and 8th to bring together nine EU-funded, mesenchymal stromal cell-focussed consortia. Projects include: REDDSTAR, REACH, RETHRIM, Stellar, MERLIN, Nephstrom, SCIENCE, VISICORT and Adipoa-2. This two day, interactive meeting will be held at the Stadsgehoorzaal Leiden.
The objectives of the meeting are to:
- Enhance knowledge-sharing between EU research groups working in the mesenchymal stromal cell biology domain
- Engage with European Commission Project Officers and other stakeholders from International Society of Cellular Therapy, stem cell ethicists and the European Medicines Agency (EMA)
- Assemble trans-disciplinary research groups working across the global health spectrum but with a common focus of mesenchymal stromal cell biology
- Bring up-and-coming researchers together for networking purposes, and to explore future consortium building and international funding application opportunities
Expected impacts and outcomes:
- Provide opportunities to develop new mesenchymal stromal cell networks
- Disseminate the findings and challenges between MSC-focussed consortia
- Improve the communication potential of research, outcomes and the value of the research
- Explore potential for new commercial technologies
- Collectively enhance the quality and impact of planned clinical trials
These EU projects are:
- Boosting human capital: 20-30 positions created
- Improving the quality of life for European citizens
- Progressing the clinical translation of MSC research and developments
For queries: LeidenRM@gmail.com
Danielle Nicholson, Orbsen Therapeutics, NUI Galway and Brigitte Wieles, Project Manager LUMC
- Contract/Grant agreement number
- EC contribution
- Starting date
1 May 2015
- Three new NEPHSTROM-acknowledged papers 3rd February 2020
- Luke Barry joins the NEPHSTROM team at Queen’s University Belfast 12th December 2019
- NEPHSTROM study published in Scientific Reports 9th December 2019
- New NEPHSTROM publication from NUI Galway team 19th November 2019
- NEPHSTROM PI Prof. Matt Griffin visits leading US medical centre Mayo Clinic to discuss EU-funded mesenchymal stromal cell projects 18th November 2019
- National University of Ireland, Galway
- Academisch Ziekenhuis Leiden – Leids Universitair Medisch Centrum
- Orbsen Therapeutics
- Ludwig-Maximilians-Universitaet Muenchen
- Istituto di Ricerche Farmacologiche Mario Negri
- NHS Blood and Transplant
- University Hospital Birmingham NHS Foundation Trust
- The Belfast Health and Social Care Trust
- Pintail Ltd
- Terumo BCT Europe N.V.
- Azienda Ospedaliera Papa Giovanni XXIII Bergamo
- Queen’s University Belfast